Creating new oral treatments for ulcerative colitis using plant cells
Engineering novel designer biologics in plant cells for oral treatment of ulcerative colitis
This study is exploring a new way to create oral medications for people with ulcerative colitis by using proteins made in plant cells, which could lead to better treatments with fewer side effects.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkansas State University NIH-funded |
| Lab location | 1 site (State University, United States) |
| Project ID | NIH-10202300 on NIH RePORTER |
What this research studies
This research focuses on developing innovative oral biologic drugs for ulcerative colitis by engineering proteins in plant cells. The approach utilizes plant cell cultures as both a production platform and a delivery vehicle for therapeutic proteins, aiming to enhance drug efficacy while minimizing side effects. By modifying these proteins with specific chemical structures, the research seeks to create a new class of anti-inflammatory agents that can be taken orally. This method could potentially improve treatment outcomes for patients suffering from inflammatory bowel disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ulcerative colitis who are seeking alternative treatment options.
Not a fit: Patients with other forms of inflammatory bowel disease, such as Crohn's disease, may not benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer oral treatment option for patients with ulcerative colitis.
How similar studies have performed: While the use of plant cells for drug production is a promising area, this specific approach to oral biologic drugs for ulcerative colitis is relatively novel and has not been extensively tested.
Where this research is happening
State University, United States
- Arkansas State University — State University, United States (Active)
Researchers
- Principal investigator: Xu, Jianfeng — Arkansas State University
- Study coordinator: Xu, Jianfeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.